Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2019 | The Moffit experience of lenalidomide and rituximab for MCL

Bijal Shah • 10 Dec 2019
ASH 2019
B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Lenalidomide Rituximab

Bijal Shah, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, outlines the Moffitt experience of lenalidomide plus rituximab in TP53-mutated mantle cell lymphoma (MCL) outside of the clinical trial setting. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Bijal Shah

The potential value of early integration of CAR-T in ALL
1:44
The potential value of early integration of CAR-T in ALL
Bijal Shah • 4 Sep 2025
Exploring strategies to optimize post-CAR-T outcomes in patients with ALL
1:15
Exploring strategies to optimize post-CAR-T outcomes in patients with ALL
Bijal Shah • 4 Sep 2025
Moving next-generation CAR constructs into ALL therapy
2:11
Moving next-generation CAR constructs into ALL therapy
Bijal Shah • 4 Sep 2025
The current role of CAR T-cell therapy in high-risk B-ALL
1:20
The current role of CAR T-cell therapy in high-risk B-ALL
Bijal Shah • 4 Sep 2025

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Bijal Shah • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Bijal Shah • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Bijal Shah • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Bijal Shah • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals